BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15788640)

  • 1. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
    Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
    Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice.
    Chen J; Hui E; Ip T; Thompson LU
    Clin Cancer Res; 2004 Nov; 10(22):7703-11. PubMed ID: 15570004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of tamoxifen on apoptosis and drug resistance of breast cancer cells in vitro].
    Zheng J; Yao Z
    Zhonghua Zhong Liu Za Zhi; 2000 Jan; 22(1):55-7. PubMed ID: 11776601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GREB 1 is a critical regulator of hormone dependent breast cancer growth.
    Rae JM; Johnson MD; Scheys JO; Cordero KE; Larios JM; Lippman ME
    Breast Cancer Res Treat; 2005 Jul; 92(2):141-9. PubMed ID: 15986123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
    Chen J; Power KA; Mann J; Cheng A; Thompson LU
    Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
    Berstein LM; Yue W; Wang JP; Santen RJ
    Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
    Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
    Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
    Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels.
    Ghayad SE; Bieche I; Vendrell JA; Keime C; Lidereau R; Dumontet C; Cohen PA
    Cancer Sci; 2008 Oct; 99(10):1992-2003. PubMed ID: 19016759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.